In a report released today, Serge Belanger from Needham maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report), with a price target of $40.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Serge Belanger has given his Buy rating due to a combination of factors, primarily focusing on NewAmsterdam Pharma’s promising developments in Alzheimer’s disease research. The company’s phase 3 BROADWAY trial results showed that their drug, obicetrapib, led to significant reductions in p-tau217, a biomarker linked to Alzheimer’s, suggesting potential cognitive benefits through improved brain cholesterol metabolism.
These findings are supported by previous studies and indicate a strong link between CETP inhibition and Alzheimer’s pathophysiology. The anticipation of further data and strategic plans to be revealed at an upcoming R&D event adds to the positive outlook. This potential for obicetrapib in addressing Alzheimer’s disease underpins Belanger’s optimistic Buy rating for NewAmsterdam Pharma.
Belanger covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Trevi Therapeutics, and Cytokinetics. According to TipRanks, Belanger has an average return of 2.9% and a 43.80% success rate on recommended stocks.